Day: June 19, 2021

VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Akome’s next generation psychedelic drug formulation for the mitigation of neurological damage resulting from ischemic strokes, also known as AKO001, is comprised of the psychedelic compound N,N-dimethyltryptamine (DMT) and a specific plant bioactive which, when combined together, are believed to work in a complementary and mitigating manner when provided to individuals immediately following their ischemic stroke. A provisional matter...

PETALING JAYA, Malaysia, June 18, 2021 (GLOBE NEWSWIRE) — Eostre Berhad, a majority-owned subsidiary of Toga Limited (OTC: TOGL), has been officially appointed by China’s Shenzhen Shengquan Biotechnology Co., Ltd., as its exclusive worldwide distributor for its product, the “H2O Energy Bottle”. Eostre is now tasked with developing a world-wide market for the “H2O energy bottles”. “We are pleased to establish this collaboration between Shenzhen Shengquan Biotechnology and Eostre. This collaboration will further grow Eostre’s product range and customer base globally,” said Eostre Berhad General Manager, Ms. Low Kah Fong. “We anticipate both companies will jointly expand the awareness and demand for the H2O energy bottle. This is also seen as being in line with Eostre’s vision of becoming an international brand with world-leading...

PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces a new line of financing through Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with Atlas, a specialized investment fund based in New York (United States), for €32 million (the “2021 Atlas Contract”). This line of financing will be used for further clinical development of Sarconeos (BIO101) in sarcopenia following our SARA phase 2 results and for...